Lightlake Therapeutics has announced that it has begun a new trial of its intranasal naloxone for the reversal of opioid overdose. According to the company, it plans to file a New Drug Application with the FDA if the results from this study are positive. Earlier this year, Lightlake announced that it had received funding for the study from the National Institute … [Read more...] about Lightlake announces new trial of intranasal naloxone for opioid overdose
Medical
Positive Phase 1 results for Milestone’s intranasal calcium channel antagonist
Milestone Pharmaceuticals has announced that a Phase 1 clinical trial of an intranasal formulation of its MSP-2017 calcium channel antagonist for possible treatment of paroxysmal supraventricular tachycardia (PSVT) showed that the drug has a rapid onset, along with other promising PK properties, and was well tolerated at doses up to 140 mg. The company said that it … [Read more...] about Positive Phase 1 results for Milestone’s intranasal calcium channel antagonist
LSTM gets grant to study nasal spray flu vaccine versus pneumococcal bacteria
The Bill and Melinda Gates Foundation has awarded a $2.5 million grant to researchers at Liverpool School of Tropical Medicine (LSTM) for a study to determine the effects of nasal spray flu vaccine on pneumococcal bacteria. The 2-year study, to be conducted in conjunction with the Royal Liverpool University Hospital, will recruit almost 300 volunteers, half of … [Read more...] about LSTM gets grant to study nasal spray flu vaccine versus pneumococcal bacteria
RespiTech team gets grant for development of inhalable Smartdrops technology
The Australian Research Council has awarded a $521,800 grant to Daniela Traini and Paul Young of the Woolcock Institute's RespiTech group and Patrick Spicer of the University of New South Wales for development of inhalable "Smartdrops" for drug delivery to the lung. The three-year project is designed to develop a microfluidics-based process for creating … [Read more...] about RespiTech team gets grant for development of inhalable Smartdrops technology
Additional Positive Phase 3 study results for AVP-825 intranasal sumatriptan
Avanir Pharmaceuticals has published results from the Phase 3 TARGET study of its AVP-825 intranasal sumatriptan powder compared to placebo for the treatment of migraine. The article appears in the January 2015 issue of Headache. Earlier this year, the company announced positive results from the Phase 3 COMPASS study that compared AVP-825 to oral … [Read more...] about Additional Positive Phase 3 study results for AVP-825 intranasal sumatriptan
Monaghan Medical presents data showing possible under-dosing from continuous nebulizers
US-based Monaghan Medical, which sells breath actuated nebulizers manufactured by Trudell Medical International (TMI), is presenting data at CHEST 2014 from a study showing that continuous nebulizers may under-dose medication. According to Monaghan changes in a patient's inspiratory/expiratory (I/E) ratio during tidal breathing can result in variable … [Read more...] about Monaghan Medical presents data showing possible under-dosing from continuous nebulizers
Sunovion reports results from dose ranging study of glycopyrrolate inhalation solution
Sunovion Pharmaceuticals has announced that all 4 dose levels of its SUN-101 glycopyrrolate inhalation solution tested in a Phase 2 study produced statistically significant improvements in lung function. The 28-day randomized, double-blind, placebo-controlled study involved more than 280 COPD patients and compared 12.5 mcg, 25 mcg, 50 mcg, and 100 mcg doses of SUN-101 … [Read more...] about Sunovion reports results from dose ranging study of glycopyrrolate inhalation solution
BI study shows Spiriva Handihaler plus Striverdi Respimat superior to Spiriva alone
Data from Boehringer Ingelheims ANHELTO 1 and ANHELTO 2 studies demonstrate that co-administration of the Spiriva HandiHaler tiotropium DPI and the Striverdi Respimat olodaterol SMI produced significantly greater improvement in the lung function of COPD patients than Spiriva alone. The company presented the data at CHEST 2014. The 12-week, double-blind studies … [Read more...] about BI study shows Spiriva Handihaler plus Striverdi Respimat superior to Spiriva alone
Study shows Anoro Ellipta improves lung function better than Spiriva Handihaler
Results from a 24-week study comparing GSK's Anoro Ellipta umeclidinium /vilanterol DPI to Boehringer Ingelheim's Spiriva Handihaler tiotropium DPI published in Respiratory Medicine show statistically greater improvement in trough FEV1 and weighted mean FEV1 0 – 6 hour post dose for UMEC/VI compared to tiotropium. The study involved a total of 905 COPD patients. … [Read more...] about Study shows Anoro Ellipta improves lung function better than Spiriva Handihaler
OrPro announces data from preclinical trial of inhaled thioredoxin
California-based biopharmaceutical company OrPro Therapeutics says that pre-clinical studies of its lead compound, ORP-100, an inhaled thioredoxin, has shown that ORP-100 reduces the viscosity and adhesiveness of the sputum of cystic fibrosis patients both in vitro and in vivo. No inflammation was observed in animals that received "many times the anticipated human … [Read more...] about OrPro announces data from preclinical trial of inhaled thioredoxin